### Overview of the PEAK1 Gene

**Gene Symbol**: PEAK1  
**Full Name**: Pseudopodium-enriched atypical kinase 1  
**Family**: Non-receptor tyrosine kinase; member of the new kinase family three (NFK3) family.

---

### 1. Associated Genes

While the summaries provided do not mention any specific genes associated directly with PEAK1, there are indirect associations and pathways it may influence that involve other genes, particularly those related to:

- **EGFR signaling pathway**: This pathway involves multiple genes such as EGFR, ERBB2, and other members of the ERBB family, influencing cell proliferation and migration.
- **Integrin signaling**: Genes like ITGβ1 (Integrin beta 1) and others involved in cell adhesion might also be associated.
- **Rho GTPase signaling**: Genes like RAC1 and CDC42 may also play a role as they are involved in regulating cell migration and cytoskeletal dynamics.

### 2. Aging and Age-Related Diseases

Current research suggests that PEAK1 may be involved in processes related to cell migration and proliferation, which can have implications for age-related conditions such as:

- **Cancer**: As PEAK1 promotes cell migration and metastasis, its dysregulation may play a role in tumor progression and could be particularly relevant in aging populations where cancer incidence increases.
- **Fibrosis**: Altered cell migration and signaling may contribute to aging-associated fibrosis in tissues such as the lungs and liver.
- **Stem cell function**: PEAK1 might influence the behavior of stem cells as they are crucial for tissue repair and regeneration, which can decline with age.

### 3. Drug Interactions

Currently, specific drug interactions with PEAK1 are not extensively documented in primary literature. However, due to its involvement in critical signaling pathways like the EGFR pathway, drugs affecting this pathway (such as:

- **EGFR inhibitors**: Such as cetuximab, gefitinib, and erlotinib.
- **Tyrosine kinase inhibitors (TKIs)**: Broadly, drugs that target tyrosine kinases in oncogenic pathways may have relevance.

These interactions suggest that any drugs or therapies designed to inhibit EGF receptor activity or its downstream signaling components may indirectly affect PEAK1 activity or regulation.

### 4. Pathways and Biological Processes

PEAK1 is involved in several key biological processes and signaling pathways, including:

- **Cell Migration**: Regulation of cell movement through focal adhesion dynamics.
- **Focal Adhesion Dynamics**: Promotion of focal adhesion formation and elongation.
- **EGFR Signaling Pathway**: Acts as a scaffold protein that integrates cellular signaling from the epidermal growth factor receptor, influencing proliferation and migration.
- **Cytoskeletal Organization**: Regulates actin cytoskeleton rearrangements, affecting cell spreading and motility.

Overall, PEAK1 is an important player in the context of cytoskeletal dynamics and cell signaling, with significant implications for cancer research and potential therapeutic approaches in oncology and age-related diseases.